Warfarin & Metronidazole Interaction

Metronidazole (Flagyl) significantly potentiates the anticoagulant effect of warfarin (Coumadin), increasing the international normalized ratio (INR) and the risk of serious or life-threatening bleeding ^[1]. This interaction is well-documented and classified as a major drug interaction requiring close monitoring or avoidance when possible ^[2]. Metronidazole inhibits the hepatic metabolism of the more potent S-enantiomer of warfarin, leading to elevated warfarin plasma concentrations and prolonged anticoagulant effect ^[1].

This interaction is clinically common because metronidazole is widely prescribed for anaerobic bacterial infections, bacterial vaginosis, Clostridioides difficile colitis, and as part of Helicobacter pylori eradication regimens, while warfarin remains one of the most commonly used anticoagulants despite the availability of direct oral anticoagulants ^[3]. Case reports have documented INR elevations exceeding 10.0 and fatal hemorrhagic events following concurrent use ^[2].

Warfarin is administered as a racemic mixture of R-warfarin and S-warfarin. S-warfarin is 3-5 times more potent as an anticoagulant and is primarily metabolized by cytochrome P450 2C9 (CYP2C9) ^[1]. Metronidazole is a moderate inhibitor of CYP2C9 and stereoselectively inhibits the metabolism of S-warfarin, leading to increased plasma concentrations of the more pharmacologically active enantiomer ^[2]. This results in enhanced inhibition of vitamin K-dependent clotting factor synthesis (factors II, VII, IX, and X) and a disproportionate increase in INR relative to the degree of CYP2C9 inhibition ^[1].

The onset of the interaction typically occurs within 2-5 days of starting metronidazole, as S-warfarin accumulates due to reduced clearance ^[2]. The effect may persist for several days after metronidazole is discontinued, as CYP2C9 activity gradually recovers and accumulated warfarin is cleared ^[3]. Patients who are CYP2C9 poor metabolizers (approximately 3-5% of the population) are at even greater risk, as their baseline warfarin clearance is already reduced ^[1].

A retrospective study found that patients on stable warfarin therapy who received metronidazole experienced a mean INR increase of 1.8 units, with 36% of patients developing supratherapeutic INR values (>4.0) ^[2]. Case reports describe INR elevations to 8.0-15.0 following standard-dose metronidazole courses, associated with gastrointestinal bleeding, intracranial hemorrhage, and hemarthrosis ^[1]. Even short courses of metronidazole (7-10 days) for common conditions like bacterial vaginosis or dental infections can produce clinically significant INR elevation ^[3]. The risk is amplified in elderly patients, those with hepatic impairment, patients on higher warfarin doses, and those concurrently taking other CYP2C9 inhibitors or antiplatelet agents ^[2]. Topical or vaginal metronidazole formulations produce lower systemic exposure but have still been reported to elevate INR in some patients, and should not be assumed free of interaction risk ^[3].

When possible, use an alternative antibiotic that does not interact with warfarin ^[1]. If metronidazole is necessary, proactively reduce the warfarin dose by 25-50% when starting metronidazole and plan for frequent INR monitoring ^[2]. Check INR within 3-5 days of starting metronidazole and at least twice weekly for the duration of the antibiotic course ^[1]. When metronidazole is discontinued, return the warfarin dose to baseline gradually and continue enhanced INR monitoring for 7-10 days to ensure the interaction has resolved ^[3]. Advise patients to watch for signs of bleeding: blood in urine or stool, black or tarry stools, unusual bruising, nosebleeds lasting more than 10 minutes, bleeding gums, heavy menstrual bleeding, severe headache (possible intracranial bleed), or any unexplained bleeding ^[1]. Vitamin K (phytonadione) should be available for INR reversal if supratherapeutic values develop ^[2].

Check INR before starting metronidazole to establish the baseline ^[1]. Repeat INR at 3-5 days after initiation, then at least twice weekly for the duration of metronidazole therapy ^[2]. Check INR 3-5 days after metronidazole is completed and again at 7-10 days, as the interaction effect may linger ^[1]. If INR exceeds the therapeutic range (typically >3.5 for most indications), reduce or hold warfarin and assess for bleeding ^[3]. If INR exceeds 5.0 without bleeding, consider low-dose oral vitamin K (1-2.5 mg) ^[2]. If INR exceeds 9.0 or active bleeding is present, administer vitamin K intravenously and consider prothrombin complex concentrate (PCC) or fresh frozen plasma depending on severity ^[1]. Monitor hemoglobin and hematocrit if bleeding is suspected ^[3].

For anaerobic infections, clindamycin is an alternative that has minimal effect on warfarin metabolism ^[1]. For Clostridioides difficile colitis, oral vancomycin or fidaxomicin are first-line treatments that do not interact with warfarin ^[3]. For bacterial vaginosis, intravaginal clindamycin cream is an alternative, though intravaginal metronidazole gel can be used with enhanced INR monitoring due to lower systemic absorption ^[2]. For Helicobacter pylori eradication, bismuth-based quadruple therapy can substitute amoxicillin for metronidazole in some regimens ^[3]. If metronidazole is the only appropriate option, the warfarin dose adjustment and intensive monitoring strategy described above should be followed ^[1]. Patients on warfarin who require long-term metronidazole should be evaluated for transition to a direct oral anticoagulant (apixaban, rivaroxaban) that is less susceptible to CYP2C9-mediated interactions, in consultation with their anticoagulation provider ^[2].